Lab
North Central Florida Neurodiagnostic Services, LLC
North Central Florida Neurodiagnostic Services, LLC was paid $1.63M by Medicaid between Jan 2018 and Oct 2023, across 49 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 28% of everything it billed.
33Billing provider infoNORTH CENTRAL FLORIDA NEURODIAGNOSTIC SERVICES, LLC
ALACHUA, FL 32615
ALACHUA, FL 32615
33aNPI1295019990assigned 09/30/2011
33bProvider typeClinical Medical Laboratory
28Total paid$1.63M
24GClaims69,024
24DCodes billed49
24AFirst – last monthJan 2018 – Oct 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#31 of 225
Median peer was paid$74K
This provider vs. median22×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,416 | $740K | |
| 2019 | 17,888 | $201K | |
| 2020 | 4,087 | $64K | |
| 2021 | 6,482 | $206K | |
| 2022 | 11,415 | $377K | |
| 2023 | 1,736 | $41K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 28% | 7,565 | 6,151 | $450K |
| 87507 | 23% | 4,478 | 3,743 | $379K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 13% | 1,961 | 1,769 | $217K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 6.1% | 6,688 | 2,107 | $100K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 4.2% | 6,671 | 5,523 | $68K |
| 87641 | 3.8% | 7,161 | 6,009 | $63K | |
| 87500 | 3.2% | 6,612 | 5,536 | $52K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.4% | 722 | 624 | $39K |
| 87506 | 2.4% | 833 | 748 | $39K | |
| 87631 | 1.9% | 365 | 310 | $31K | |
| 87481 | 1.5% | 3,838 | 2,621 | $25K | |
| 87640 | 1.4% | 3,127 | 2,637 | $23K |
37 more codes
| 87653 | 1.4% | 2,733 | $23K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,415 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,419 | $14K |
| 87486 | <1% | 1,175 | $14K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,674 | $13K |
| 87581 | <1% | 1,168 | $13K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,427 | $11K |
| 87511 | <1% | 1,210 | $8K | |
| 87625 | <1% | 1,238 | $8K | |
| 81404 | <1% | 922 | $3K | |
| 81321 | <1% | 184 | $3K | |
| 81334 | <1% | 182 | $2K | |
| 81235 | <1% | 182 | $2K | |
| 81162 | <1% | 173 | $2K | |
| 81272 | <1% | 181 | $2K | |
| 81408 | <1% | 346 | $2K | |
| 87799 | <1% | 293 | $1K | |
| 81403 | <1% | 366 | $1K | |
| 81401 | <1% | 361 | $985.20 | |
| 81407 | <1% | 171 | $778.57 | |
| 81201 | <1% | 171 | $717.60 | |
| 81317 | <1% | 173 | $650.46 | |
| 81292 | <1% | 171 | $621.37 | |
| 81298 | <1% | 171 | $590.50 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13 | $516.63 |
| 81295 | <1% | 171 | $351.16 | |
| 81405 | <1% | 348 | $277.24 | |
| 81406 | <1% | 346 | $260.25 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 20 | $186.15 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 29 | $175.48 |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 15 | $124.75 |
| 81209 | <1% | 169 | $36.17 | |
| 81242 | <1% | 171 | $33.69 | |
| 87471 | <1% | 16 | $28.00 | |
| 87529 | <1% | 16 | $28.00 | |
| 81345 | 0% | 168 | $0.00 | |
| 87532 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARPER, ADRIAN (PRESIDENT AND CEO)